| 2026-08-17 | Press release | OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates |
| 2026-08-13 | Press release | OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 i |
| 2026-07-08 | Press release | OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program |
| 2026-07-06 | Press release | Read Press Release |
| 2026-07-02 | Press release | OS Therapies Appoints Dr. Craig Eagle to Board of Directors |
| 2026-06-30 | Press release | OS Therapies Provides U.S. Regulatory Update |
| 2026-06-26 | Press release | OS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Fr |
| Press release | Read Press Release |
| Press release | Read Press Release |
| Press release | Read Press Release |
| Press release | Read Press Release |
| 2026-05-18 | Press release | OS Therapies Reports First Quarter 2026 Financials and Provides Business Update |
| 2026-05-18 | Press release | Earnings Release |
| 2026-04-27 | Press release | OS Therapies Schedules OST-HER2 Pharmacodynamic Response Biomarker Conference Call on April 30, 2026 at 8:30am ET |
| 2026-01-12 | Press release | OS Therapies Enters into Warrant Inducement Agreements |
| 2026-01-05 | Press release | OS Therapies Provides First Half 2026 Corporate Outlook |
| 2025-12-10 | Presentation | Corporate Presentation - December 2025 |
| 2025-10-21 | Presentation | 2-page Summary |
| 2025-10-07 | Press release | OS Therapies to Participate in Fall 2025 Conferences and Events |
| 2025-09-19 | Press release | OS Therapies to Participate in Spotlight Panel at BioFuture 2025 October 13 11:00am EDT |
| 2025-09-02 | Press release | OS Therapies Provides OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Program Update Following FDA |
| 2025-08-27 | Press release | OS Therapies to Provide OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma FDA End of Phase 2 Meeting |
| 2025-04-02 | Press release | OS Therapies to Host Analyst Day at NYSE on April 7, 2025 |
| 2025-03-31 | Press release | PDF: OS Therapies Reports Full Year 2024 Financial Results and Provides Business Update |
| 2025-02-26 | Press release | Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on February 27 |
| 2024-11-15 | Press release | PDF: OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update |
| 2024-11-04 | Press release | OS Therapies to Present at The Spartan Capital Investor Conference |
| 2024-08-15 | Press release | Earnings Release |
| 2024-08-15 | Press release | HTML |
| 2024-08-15 | Press release | PDF: OS Therapies Reports Second Quarter 2024 Financial Results |
| Press release | Earnings Release |
| Press release | Earnings Release |
| Press release | OS Therapies Reports Full Year 2024 Financial Results and Provides Business Update |
| Press release | HTML |